Artificial Intelligence in Drug Repurposing Market Trends Pharma Can't Ignore
The global artificial intelligence in drug repurposing market stood at USD 1.3 billion in 2025 and is forecast to climb to USD 7.7 billion by 2033, growing at a CAGR of 24.5% between 2026 and 2033. North America leads with 52.9% share, oncology is the top application at 36.7%, and software & platform tools account for 66.6% of spend. Baricitinib was designed as a rheumatoid arthritis drug. Within months of the COVID-19 outbreak, BenevolentAI's platform flagged it as a candidate for the virus, and by late 2020 it had emergency FDA authorization for exactly that use. That single case did more to legitimize AI-driven drug repurposing than a decade of academic papers — it proved a known, already-safety-tested compound could be redeployed against a brand-new disease in months, not years. That proof point is now the engine behind a market moving at nearly 25% annual growth. What Is Driving Growth in This Market? Traditional drug discovery is simply too slow and too expensive to ...